DENVER, CO--(Marketwire - Apr 5, 2012) - Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: [ OMBP ]), a biopharmaceutical company, today announced that the Company will host a shareholder and investor conference call beginning at 2:30 p.m. MDT (4:30 p.m. EDT) on Tuesday, April 17, 2012. Please join Company management for an update and plans for the coming year, which will include a question and answer session.

Individuals interested in listening to the conference call may do so by dialing 866-225-8754 for domestic callers, or 480-629-9818 for international callers.

A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing 800-406-7325 for domestic callers, or 303-590-3030 for international callers, and entering reservation code 4530720.

An audio replay will also be available on the Company's website [ www.omnibiopharma.com ] for 14 days following the completion of the call.

About Omni Bio

Omni Bio Pharmaceutical ([ www.omnibiopharma.com ]) is a biopharmaceutical company that is focused on developing a new drug ("Fc-AAT") that can be applied to the treatment of a broad range of inflammatory and immune diseases. This drug is a fusion protein that will be made by recombinant technology and we believe would be appropriate for treatment of Type 1 diabetes, complications due to bone marrow transplantation referred to as graft versus host disease, acute myocardial infarction and inflammatory bowel disease. Since its formation, Omni Bio has supported research in both animal models and in human studies that demonstrate that the human protein Alpha-1 antitrypsin ("AAT") has unique and highly potent anti-inflammatory and immune modifying functions. This research provides the foundation for our development of our new drug, Fc-AAT.

Fc-AAT is a fusion protein that combines human AAT with the Fc fragment of human IgG. We believe our technology is similar to that already used to create highly successful drugs for human application such as Enbrel. In a variety of in vitro (cell based) and in vivo (animal) models Fc-AAT was found to be 100 to 1,000 times more potent than plasma-derived AAT in terms of modulation of critical inflammatory pathways. Recombinant technology can potentially produce AAT in a laboratory environment at substantially lower cost and in higher volumes than can be accomplished by purifying AAT from human plasma sources.

Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements that reflect management's current views and expectations with respect to future events and plans, including with respect to the scientific potential and development of Fc-AAT, capital needs, and Omni's goals and steps in commercializing Fc-AAT. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to receipt of adequate funding to operate as a going concern and fund the commercialization of Fc-AAT; issuance of patents relating to Fc-AAT; receipt of applicable FDA and other regulatory approvals; success of the clinical trials; ability to otherwise successfully commercialize Fc-AAT; and the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.